<p>泰利福（NYSE:TFX - 獲取免費報告）在週六發佈的報告中被華爾街 Zen 的研究分析師從 “持有” 評級下調至 “賣出” 評級。</p>
<p>其他一些分析師最近也對 TFX 發表了看法。雷蒙德·詹姆斯金融公司在週五的研究報告中重申了 “跑贏大盤” 評級，並將泰利福的目標股價設定為 150.00 美元。韋斯評級在 3 月 27 日的研究報告中重申了泰利福的 “賣出（d）” 評級。加拿大皇家銀行將泰利福的評級從 “行業表現” 上調至 “跑贏大盤”，並將其目標股價從 135.00 美元提高至 155.00 美元。瑞穗證券在週五為泰利福設定了 140.00 美元的目標股價。最後，美國銀行在 4 月 13 日的研究報告中將泰利福的評級從 “表現不佳” 上調至 “中性”，併為該公司設定了 135.00 美元的目標股價。三位投資分析師對該股票給予了買入評級，五位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，泰利福目前的平均評級為 “持有”，平均目標股價為 142.86 美元。</p>
<p><strong>查看我們對 TFX 的最新分析</strong></p>
<h2>泰利福股票上漲 1.1%</h2>
<p>週五，泰利福股票開盤價為 133.17 美元。泰利福的 12 個月低點為 100.18 美元，12 個月高點為 139.67 美元。該股票的 50 日移動平均線為 119.44 美元，200 日移動平均線為 116.73 美元。公司的流動比率為 2.55，速動比率為 2.01，債務與股本比率為 0.82。該股票的市值為 58.9 億美元，市盈率為-5.84，PEG 比率為 0.95，貝塔值為 0.82。</p>
<p>泰利福（NYSE:TFX - 獲取免費報告）最後一次發佈季度財報是在 5 月 7 日，醫療技術公司報告該季度每股收益為 1.39 美元，超出分析師一致預期的 1.21 美元，超出幅度為 0.18 美元。泰利福的股本回報率為 13.29%，淨利潤率為-35.88%。該公司在該季度的收入為 5.483 億美元，而分析師預期為 5.3691 億美元。去年同期，該公司每股收益為 1.44 美元。該公司的季度收入同比增長 32.3%。泰利福已將其 2026 財年的每股收益指引設定為 6.250-6.550 美元。整體來看，研究分析師預計泰利福在當前年度的每股收益將達到 6.75 美元。</p>
<h2>對泰利福的對沖基金看法</h2>
<p>一些大型投資者最近調整了對該公司的持股。Janus Henderson Group PLC 在第四季度將其在泰利福股票中的持股比例提高了 2.0%。Janus Henderson Group PLC 目前擁有 4,246,112 股醫療技術公司的股票，價值 518,196,000 美元，此前在上個季度又購買了 84,754 股。AQR 資本管理公司在第三季度將其在泰利福股票中的持股比例提高了 478.1%。AQR 資本管理公司目前擁有 2,366,131 股醫療技術公司的股票，價值 287,603,000 美元，此前在上個季度又購買了 1,956,811 股。道富銀行在第四季度將其在泰利福股票中的持股比例提高了 1.5%。道富銀行目前擁有 1,478,776 股醫療技術公司的股票，價值 180,470,000 美元，此前在上個季度又購買了 22,111 股。Dimensional Fund Advisors LP 在第四季度將其在泰利福股票中的持股比例提高了 0.4%。Dimensional Fund Advisors LP 目前擁有 1,250,665 股醫療技術公司的股票，價值 152,630,000 美元，此前在上個季度又購買了 5,051 股。最後，Cooke &amp; Bieler LP 在第三季度將其在泰利福股票中的持股比例提高了 1.2%。Cooke &amp; Bieler LP 目前擁有 1,220,637 股醫療技術公司的股票，價值 149,357,000 美元，此前在上個季度又購買了 14,673 股。95.62% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>影響泰利福的關鍵故事</h2>
<p>以下是本週影響泰利福的關鍵新聞：</p>
<ul>
<li>積極情緒：泰利福超出第一季度預期，報告調整後每股收益為 1.39 美元，而預期為 1.21 美元，收入為 5.483 億美元，而預期為 5.369 億美元，顯示出該季度的穩健執行。文章標題</li>
<li>積極情緒：該公司維持其 2026 財年的整體展望，並宣佈回購計劃，這可以支持投資者信心和股價表現。文章標題</li>
<li>積極情緒：富國銀行將 TFX 的目標股價從 130 美元上調至 138 美元，暗示當前水平有適度上行空間，並表明分析師情緒改善。文章標題</li>
<li>中性情緒：管理層的財報電話會議評論被描述為平衡，增長被利潤率壓力抵消，表明儘管財報超出預期，但業務仍在應對盈利壓力。文章標題</li>
<li>消極情緒：泰利福更新的 2026 財年每股收益指引為 6.25 至 6.55 美元，低於市場預期的約 6.73 美元，儘管季度業績超出預期，但可能限制熱情。文章標題</li>
</ul>
<h2>關於泰利福</h2>
<p>（獲取免費報告）</p>
<p>泰利福公司是一家多元化的全球醫療技術提供商，專注於危重護理和外科手術。公司總部位於賓夕法尼亞州韋恩，設計、製造和分銷醫療專業人員在醫院、門診和其他場所使用的設備和解決方案。泰利福專注於提供支持複雜介入程序並改善患者結果的產品。</p>
<p>公司的產品涵蓋多個關鍵領域，包括介入泌尿學、呼吸與麻醉、外科、心臟護理、血管和原始設備製造商（OEM）解決方案。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比泰利福更具吸引力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRGWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRGWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Teleflex 嗎？</h2>
<p>在考慮 Teleflex 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Teleflex 並不在名單上。</p>
<p>雖然 Teleflex 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

泰利福

<p>華爾街禪將 Teleflex（紐約證券交易所代碼：TFX）的評級從 “持有” 下調至 “賣出”。其他分析師的看法不一，Raymond James 維持 “跑贏大盤” 評級，目標價為 150 美元，而 Weiss Ratings 重申 “賣出” 評級。Teleflex 的股票開盤價為 133.17 美元，12 個月高點為 139.67 美元。該公司報告第一季度每股收益為 1.39 美元，超出預期，營收為 5.483 億美元。對沖基金持有該股票的 95.62%，顯示出強烈的機構興趣</p>

<p>Teleflex (NYSE:TFX - Get Free Report) was downgraded by research analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report issued on Saturday.</p>
<div class="lb-trans"><p>泰利福（NYSE:TFX - 獲取免費報告）在週六發佈的報告中被華爾街 Zen 的研究分析師從 “持有” 評級下調至 “賣出” 評級。</p>
</div><p>A number of other analysts have also recently weighed in on TFX. Raymond James Financial reaffirmed an &#34;outperform&#34; rating and set a $150.00 price objective on shares of Teleflex in a research report on Friday. Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of Teleflex in a research report on Friday, March 27th. Royal Bank Of Canada raised Teleflex from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating and increased their price objective for the stock from $135.00 to $155.00 in a research report on Friday. Mizuho set a $140.00 price objective on Teleflex in a research report on Friday. Finally, Bank of America raised Teleflex from an &#34;underperform&#34; rating to a &#34;neutral&#34; rating and set a $135.00 price objective for the company in a research report on Monday, April 13th. Three investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Teleflex currently has an average rating of &#34;Hold&#34; and an average target price of $142.86.</p>
<div class="lb-trans"><p>其他一些分析師最近也對 TFX 發表了看法。雷蒙德·詹姆斯金融公司在週五的研究報告中重申了 “跑贏大盤” 評級，並將泰利福的目標股價設定為 150.00 美元。韋斯評級在 3 月 27 日的研究報告中重申了泰利福的 “賣出（d）” 評級。加拿大皇家銀行將泰利福的評級從 “行業表現” 上調至 “跑贏大盤”，並將其目標股價從 135.00 美元提高至 155.00 美元。瑞穗證券在週五為泰利福設定了 140.00 美元的目標股價。最後，美國銀行在 4 月 13 日的研究報告中將泰利福的評級從 “表現不佳” 上調至 “中性”，併為該公司設定了 135.00 美元的目標股價。三位投資分析師對該股票給予了買入評級，五位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，泰利福目前的平均評級為 “持有”，平均目標股價為 142.86 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on TFX</strong></p>
<div class="lb-trans"><p><strong>查看我們對 TFX 的最新分析</strong></p>
</div><h2>Teleflex Stock Up 1.1%</h2>
<div class="lb-trans"><h2>泰利福股票上漲 1.1%</h2>
</div><p>Teleflex stock opened at $133.17 on Friday. Teleflex has a twelve month low of $100.18 and a twelve month high of $139.67. The stock has a 50 day moving average of $119.44 and a two-hundred day moving average of $116.73. The company has a current ratio of 2.55, a quick ratio of 2.01 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $5.89 billion, a price-to-earnings ratio of -5.84, a PEG ratio of 0.95 and a beta of 0.82.</p>
<div class="lb-trans"><p>週五，泰利福股票開盤價為 133.17 美元。泰利福的 12 個月低點為 100.18 美元，12 個月高點為 139.67 美元。該股票的 50 日移動平均線為 119.44 美元，200 日移動平均線為 116.73 美元。公司的流動比率為 2.55，速動比率為 2.01，債務與股本比率為 0.82。該股票的市值為 58.9 億美元，市盈率為-5.84，PEG 比率為 0.95，貝塔值為 0.82。</p>
</div><p>Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts' consensus estimates of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The company had revenue of $548.30 million during the quarter, compared to analysts' expectations of $536.91 million. During the same period last year, the firm earned $1.44 EPS. The firm's revenue for the quarter was up 32.3% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, research analysts expect that Teleflex will post 6.75 earnings per share for the current year.</p>
<div class="lb-trans"><p>泰利福（NYSE:TFX - 獲取免費報告）最後一次發佈季度財報是在 5 月 7 日，醫療技術公司報告該季度每股收益為 1.39 美元，超出分析師一致預期的 1.21 美元，超出幅度為 0.18 美元。泰利福的股本回報率為 13.29%，淨利潤率為-35.88%。該公司在該季度的收入為 5.483 億美元，而分析師預期為 5.3691 億美元。去年同期，該公司每股收益為 1.44 美元。該公司的季度收入同比增長 32.3%。泰利福已將其 2026 財年的每股收益指引設定為 6.250-6.550 美元。整體來看，研究分析師預計泰利福在當前年度的每股收益將達到 6.75 美元。</p>
</div><h2>Hedge Funds Weigh In On Teleflex</h2>
<div class="lb-trans"><h2>對泰利福的對沖基金看法</h2>
</div><p>A number of large investors have recently modified their holdings of the business. Janus Henderson Group PLC raised its stake in shares of Teleflex by 2.0% during the 4th quarter. Janus Henderson Group PLC now owns 4,246,112 shares of the medical technology company's stock worth $518,196,000 after buying an additional 84,754 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Teleflex by 478.1% during the 3rd quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company's stock worth $287,603,000 after buying an additional 1,956,811 shares in the last quarter. State Street Corp raised its stake in shares of Teleflex by 1.5% during the 4th quarter. State Street Corp now owns 1,478,776 shares of the medical technology company's stock worth $180,470,000 after buying an additional 22,111 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Teleflex by 0.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company's stock worth $152,630,000 after buying an additional 5,051 shares in the last quarter. Finally, Cooke &amp; Bieler LP raised its stake in shares of Teleflex by 1.2% during the 3rd quarter. Cooke &amp; Bieler LP now owns 1,220,637 shares of the medical technology company's stock worth $149,357,000 after buying an additional 14,673 shares in the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了對該公司的持股。Janus Henderson Group PLC 在第四季度將其在泰利福股票中的持股比例提高了 2.0%。Janus Henderson Group PLC 目前擁有 4,246,112 股醫療技術公司的股票，價值 518,196,000 美元，此前在上個季度又購買了 84,754 股。AQR 資本管理公司在第三季度將其在泰利福股票中的持股比例提高了 478.1%。AQR 資本管理公司目前擁有 2,366,131 股醫療技術公司的股票，價值 287,603,000 美元，此前在上個季度又購買了 1,956,811 股。道富銀行在第四季度將其在泰利福股票中的持股比例提高了 1.5%。道富銀行目前擁有 1,478,776 股醫療技術公司的股票，價值 180,470,000 美元，此前在上個季度又購買了 22,111 股。Dimensional Fund Advisors LP 在第四季度將其在泰利福股票中的持股比例提高了 0.4%。Dimensional Fund Advisors LP 目前擁有 1,250,665 股醫療技術公司的股票，價值 152,630,000 美元，此前在上個季度又購買了 5,051 股。最後，Cooke &amp; Bieler LP 在第三季度將其在泰利福股票中的持股比例提高了 1.2%。Cooke &amp; Bieler LP 目前擁有 1,220,637 股醫療技術公司的股票，價值 149,357,000 美元，此前在上個季度又購買了 14,673 股。95.62% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Key Stories Impacting Teleflex</h2>
<div class="lb-trans"><h2>影響泰利福的關鍵故事</h2>
</div><p>Here are the key news stories impacting Teleflex this week:</p>
<div class="lb-trans"><p>以下是本週影響泰利福的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: Teleflex beat Q1 estimates, reporting adjusted EPS of $1.39 versus $1.21 expected and revenue of $548.3 million versus $536.9 million expected, which signals solid execution in the quarter. Article Title</li>
<li>Positive Sentiment: The company maintained its full-year 2026 outlook and announced plans for a buyback, which can support investor confidence and share price performance. Article Title</li>
<li>Positive Sentiment: Wells Fargo raised its price target on TFX from $130 to $138, implying modest upside from current levels and suggesting improved analyst sentiment. Article Title</li>
<li>Neutral Sentiment: Management’s earnings call commentary was described as balanced, with growth offset by margin strain, indicating the business is still navigating profitability pressure even after the earnings beat. Article Title</li>
<li>Negative Sentiment: Teleflex’s updated FY2026 EPS guidance of $6.25 to $6.55 came in below the market’s expectation of about $6.73, which could limit enthusiasm despite the quarterly beat. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：泰利福超出第一季度預期，報告調整後每股收益為 1.39 美元，而預期為 1.21 美元，收入為 5.483 億美元，而預期為 5.369 億美元，顯示出該季度的穩健執行。文章標題</li>
<li>積極情緒：該公司維持其 2026 財年的整體展望，並宣佈回購計劃，這可以支持投資者信心和股價表現。文章標題</li>
<li>積極情緒：富國銀行將 TFX 的目標股價從 130 美元上調至 138 美元，暗示當前水平有適度上行空間，並表明分析師情緒改善。文章標題</li>
<li>中性情緒：管理層的財報電話會議評論被描述為平衡，增長被利潤率壓力抵消，表明儘管財報超出預期，但業務仍在應對盈利壓力。文章標題</li>
<li>消極情緒：泰利福更新的 2026 財年每股收益指引為 6.25 至 6.55 美元，低於市場預期的約 6.73 美元，儘管季度業績超出預期，但可能限制熱情。文章標題</li>
</ul>
</div><h2>About Teleflex</h2>
<div class="lb-trans"><h2>關於泰利福</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.</p>
<div class="lb-trans"><p>泰利福公司是一家多元化的全球醫療技術提供商，專注於危重護理和外科手術。公司總部位於賓夕法尼亞州韋恩，設計、製造和分銷醫療專業人員在醫院、門診和其他場所使用的設備和解決方案。泰利福專注於提供支持複雜介入程序並改善患者結果的產品。</p>
</div><p>The company's offerings span several key segments, including Interventional Urology, Respiratory &amp; Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.</p>
<div class="lb-trans"><p>公司的產品涵蓋多個關鍵領域，包括介入泌尿學、呼吸與麻醉、外科、心臟護理、血管和原始設備製造商（OEM）解決方案。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Teleflex</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比泰利福更具吸引力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRGWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=TFX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Teleflex Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Teleflex 嗎？</h2>
</div><p>Before you consider Teleflex, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Teleflex 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意到之前購買的股票……而 Teleflex 並不在名單上。</p>
</div><p>While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Teleflex 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

泰利福（NYSE: TFX）在華爾街 Zen 的評級被下調至賣出